Elevated result

Understanding an elevated result

A guide to understanding risk and taking action

Health. Illuminated.

Elevated result

Understanding your Myriad MyRisk
hereditary cancer test result

Breast cancer RiskScore™

™

You may or may not see a breast cancer RiskScore and/or a Tyrer-Cuzick breast cancer risk assessment in thissection of the report. This is calculated for women whomeet certain criteria and have never been diagnosed withbreast cancer themselves.

CONFIDENTIAL*54501233*
54501233

MyRisk Genetic Result

Name: Pt Last Name, Pt First Name

DOB: Dec 03, 1982

Accession #: 07007255-BLD

Report Date: Dec 03, 2021

Breast Cancer RiskScore®

Breast Cancer®
RiskScore :RESULT:

35.3%

35.3% Remaining Lifetime Breast Cancer Risk
1.7% 5-Year Breast Cancer Risk

Remaining Lifetime Breast Cancer Risk (Age-Adjusted)
GeneralPopulation

Your Myriad Genetics MyRisk Hereditary Cancer test has three main sections which
are summarized in the banner on the first page. Throughout the report, these
sections can be identified by the title on the top left of each page of the report.

0This means that no clinically significant mutations were foundin any of the genes analyzed as part of your testing. This does
not mean that you have no cancer risk; it means that you did notinherit a harmful genetic change in any of the genes analyzed.
Additionally, you cannot pass a clinically significant mutation inthese genes to your children.
If your result includes a variant of uncertain clinical significance(VUS), it will also be listed in the genetic result part of yourreport. A VUS is a genetic change that may or may not be
contributing to your cancer risk. A VUS is not considered to
be clinically actionable, so medical care decisions should not
be made based on a VUS. We are committed to identifying
information so that we can better understand these genetic
changes. If new information is available about your specific VUS,
that information will be shared with your healthcare provider.
Your negative result DOES NOT mean that other relatives, suchas your brothers and sisters, parents, aunts and uncles, cousins,or other family members do not have a harmful genetic changethat could increase their risk for cancer. If there is a family
history of cancer, your relatives should still discuss their history
with their own health care providers.

15

20

25

30

35

40

45

50

The breast cancer RiskScore provides an estimate of the remaining lifetime risk for breast cancer. A risk estimate at or above 20% is
associated with specific modified medical recommendations, including consideration of more aggressive breast cancer screening andadditional risk reduction measures. If applicable, details of these recommendations are provided in the accompanying MyRisk Medical
Management Tool or other supplemental material. Women with a risk estimate below 20% may still be appropriate for consideration ofmodified medical management based on other clinical factors or estimates from other breast cancer risk models, such as Tyrer-Cuzick,
Claus, and Gail.

REMAINING LIFETIME BREAST CANCER RISK: 18.5%

5-YEAR BREAST CANCER RISK: 0.8%

The National Comprehensive Cancer Network (NCCN) provides medical management recommendations for women with an estimatedremaining lifetime breast cancer risk greater than 20% based on Tyrer-Cuzick. These recommendations are summarized on the MyRisk
Management Tool (MMT). If an MMT is not included with this report, current management recommendations from the NCCN Breast
Cancer Screening and Diagnosis panel can be accessed at www.nccn.org. Version 7.02 of the Tyrer-Cuzick model was used for this risk
estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials website, http://www.ems-trials.org/
riskevaluator.

Clinical & cancer
family history information
2

Your genetic result was NEGATIVE!

10

TYRER-CUZICK BREAST CANCER RISK CALCULATION

3 Management tool

The MyRisk test looks at multiple genes associated with hereditarycancer risk. When a gene has a clinically significant mutation, ora harmful change, there is a higher chance for certain cancers todevelop. A list of the genes evaluated on your test can be found in
this section of your report. The gene table on our website includes
information about each gene and the cancers with which it isassociated (see Resources section for link).

5

BREAST CANCER RISKSCORE® INTERPRETATION

2 Clinical & cancer family history information

Genetic result

35.3%This Patient

1 Genetic result

1

20% Risk
Threshold

13.0%

CONFIDENTIAL*54501233*
54501233

Integrated BRACAnalysis® with MyRisk

TM

Hereditary Cancer Test

MyRisk Genetic Result
RECEIVING HEALTHCARE PROVIDER

SPECIMEN

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1982

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

PATIENT

Dec 03, 2021

Name:

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007255-BLD

Requisition #: 90026826

The Clinical & Cancer Family History Information section
reviews the medical information that your healthcare
provider gave us about you and your family. Certain typesof cancer in the family, or cancers diagnosed at early ages
can indicate that someone may have an elevated risk,even if no clinically significant mutations are found.

CONFIDENTIAL*54501233*
54501233® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
TM
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

Integrated BRACAnalysis® with MyRisk

Hereditary Cancer Test

MyRisk Genetic Result
Page 3 of 4

Clinical & Cancer Family History Information
RECEIVING HEALTHCARE PROVIDER

SPECIMEN

Test HCP, MD

Specimen Type: Blood

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1982

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

PATIENT

Dec 03, 2021

Name:

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007255-BLD

Requisition #: 90026826
PERSONAL / FAMILY CANCER HISTORY SUMMARYFAMILY MEMBERCANCER / CLINICAL DIAGNOSIS

Patient

None

Aunt Paternal

Breast, Invasive

AGE AT DIAGNOSIS62

PATIENT CLINICAL HISTORY SUMMARYGENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED

Woman's age

39

Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

Ancestry

White/Non-Hispanic- HRT: Treatment Type

N/A

- HRT: Current user

N/A

BREAST CANCER RISKSCORE : REMAINING LIFETIME RISK 35.3%®

This level of risk is at or above 20% threshold for consideration of modified medical management.
See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIEDBASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.

Hormone Replacement Therapy (HRT)

Height5 ft 7 in

Weight175 lbs- Number of years ago started

Age of menarche

13- Additional years of intended use

Patient's menopausal status

Pre-menopausal- Age of onset

NUMBER OF PATIENT'S FEMALE RELATIVES

Details About Non-Clinically Significant Variants: All individuals carry DNA changes (i.e., variants), and most variants do not increase anindividual's risk of cancer or other diseases. When identified, variants of uncertain significance (VUS) are reported. Likely benign variants(Favor Polymorphisms) and benign variants (Polymorphisms) are not reported and available data indicate that these variants most likely do
not cause increased cancer risk. Present evidence does not suggest that non-clinically significant variant findings be used to modify patient
medical management beyond what is indicated by the personal and family history and any other clinically significant findings.

Daughters

1

N/A
N/A

- Number of years ago ended

27

ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIED

N/A- HRT: Past user

N/A

Age of first live birth

No

N/A

Breast biopsy

Sisters2

Not Specified

Maternal Aunts

2

Paternal Aunts

2

TM

Variant Classification: Myriad's myVision Variant Classification Program performs ongoing evaluations of variant classifications. In certain
cases, healthcare providers may be contacted for more clinical information or to arrange family testing to aid in variant classification. When
new evidence about a variant is identified and determined to result in clinical significance and management change, that information willautomatically be made available to the healthcare provider through an amended report.

3® 2021 Myriad Genetics, Inc. | 320 Wakara Way, Salt Lake City, Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615
The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

MyRisk Genetic Result
Page 1 of 4

Management tool

In addition to the genetic result, the presence of certain
cancers in the family or certain medical findings in your own
health history can also influence your cancer risk. There may
be additional recommendations from expert medical groups
listed in this section due to these personal or family history
health factors.

CONFIDENTIAL*54501233*
54501233

TM
Integrated BRACAnalysis®
with
MyRiskTest® 2021MyriadGenetics, Inc.Hereditary| 320 Wakara Way,Cancer
Salt Lake City,
Utah 84108 | PH: 1-800-469-7423 FX: 801-584-3615

MyRisk Management Tool

The format and contents of this report are proprietary and may not be copied or used without permission, except for purposes ofdiagnosing, counseling and treating the patient identified in the report and members of his or her family. Myriad, Myriad MyRisk,
RiskScore, BRACAnalysis, COLARIS, myVision and their respective logos are either trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and other jurisdictions.

RECEIVING HEALTHCARE PROVIDER

SPECIMENPATIENT

Test HCP, MD

Specimen Type: Blood

Name:

Test Medical Center

Draw Date:

Dec 03, 2021

Pt First Name

6609 BLANCO RD STE 200

Accession Date: Dec 03, 2021

Date of Birth: Dec 03, 1982

Report Date:

Patient ID:

SAN ANTONIO, TX 78216

Dec 03, 2021

Clinical Information
Page 1 of 2

Pt Last Name,

Patient id

Gender:FemaleAccession #:07007255-BLD

Requisition #: 90026826

GENETIC RESULT: NEGATIVE - NO CLINICALLY SIGNIFICANT MUTATION IDENTIFIED
Note: "CLINICALLY SIGNIFICANT," as defined in this report, is a genetic change that is associated with thepotential to alter medical intervention.

BREAST CANCER RISKSCORE®: REMAINING LIFETIME RISK 35.3%

If there are recommendations for changes to your breast
cancer screening based on your RiskScore and/or a TyrerCuzick breast cancer risk assessment, they will be includedin this section.

This level of risk is at or above 20% threshold for consideration of modified medical management.
See RiskScore Interpretation Section for more information.

CLINICAL HISTORY ANALYSIS: NO ADDITIONAL MANAGEMENT GUIDELINES IDENTIFIEDBASED ON THE CLINICAL HISTORY PROVIDED
Other clinical factors may influence individualized management. This analysis may be incomplete if details about
cancer diagnoses, ages, family relationships or other factors were omitted or ambiguous. If this patient also has aclinically significant mutation, the recommendations based on the clinical history analysis should be considered inlight of the possibility that this mutation explains all or some of the cancer history in the family.
BREAST CANCER RISKSCORE®

At or above 20%

Personal and family histories can change over time, so it
is important to keep your healthcare providers up to dateregarding any changes.

THIS BREAST CANCER RISKSCORE IS ASSOCIATED WITH
THE FOLLOWING CANCER RISKS:®

ELEVATED RISK: Female Breast

No clinically significant mutations were identified in this patient. However, based on personal/family history, the patient's cancer risks may
still be increased over the general population. See information below.
Please see the Genetic Test Result for more details on any variant(s) detected in this patient, including variant classification information.
ADDITIONAL FINDINGS: NO VARIANT(S) OF UNCERTAIN SIGNIFICANCE (VUS) IDENTIFIEDTYRER-CUZICK BREAST CANCER RISK CALCULATIONREMAINING LIFETIME BREAST CANCER RISK: 18.5%

5-YEAR BREAST CANCER RISK: 0.8%

The Tyrer-Cuzick breast cancer risk estimate is only calculated for women who meet the following criteria: 1) age is younger than 85 years,2) no known mutation or inconclusive result has been found in the woman or any of her relatives, and 3) the sample was submitted with acurrent Test Request Form that includes all of the fields required to collect the information used in the calculation, and the provider has
not indicated on the Test Request Form that the Tyrer-Cuzick calculation is not appropriate for the patient. Version 7.02 of the TyrerCuzick model was used for this risk estimate. Tyrer-Cuzick model Versions 7.02 and 8.0 are available for download at the EMS-Trials
website, http://www.ems-trials.org/riskevaluator.

CLINICAL OVERVIEW OF GENETIC FINDINGS

ResourcesYour healthcare provider is always your primary resource. You can findadditional information and educational material at www.mysupport360.com.
You can request a consultation with a certified genetic counselor at Myriad
by going to my.myriad.com/consults. During your consultation, the genetic
counselor can help you understand your report and the implications of yourresults.
To view the full list of genes available on the MyRisk™ panel, please visit:www.myriadmyrisk.com/gene-table/

Next steps
Schedule any follow-up appointments and/or obtain referrals toappropriate specialists
Speak with your relatives about your results and encourage them to see
their healthcare provider about cancer prevention and genetic testing
Consider speaking with a clinical genetic counselor or other genetics
expert in your community about your test result and family history

Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT
84108
myriad.com

Myriad, the Myriad logo, Myriad myRisk, the Myriad myRisk logo, riskScore
the riskScore logo, mySupport360, and the mySupport360 logo are either
trademarks or registered trademarks of Myriad Genetics, Inc. in the UnitedStates and other jurisdictions.
©2022, Myriad Genetic Laboratories, Inc.
MGMRHCELEVPET / 02-22